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Background: The effect of cardiac pacing on sleep-disordered breathing is controversial. We investigated
the long-term effect of cardiac pacing on sleep disordered breathing in patients with conventional
indications for permanent pacemakers
Methods: Subjects comprised 40 patients (29 men; mean age 6979 years, mean left ventricle ejection
fraction 6978%, and body mass index 23.673.5 kg/m2) who were diagnosed with indications for
permanent pacemakers (sick sinus syndrome in 23 patients, atrioventricular block in 15, and brady atrial
ﬁbrillation in 2). All patients received polysomnographic evaluations before implantation of permanent
pacemakers. After implantation of permanent pacemakers, all patients received polysomnographic
evaluations during use of the pacemaker settings (AAI/DDD/VVI at 70 beats per minute).
Results: The mean follow-up period was 35713 months. Before implantation, the distribution of sleep-
disordered breathing was as follows: 93% had apnea hypopnea index 45, 58% had apnea hypopnea
index 415, and 20% had apnea hypopnea index 430. The mean apnea hypopnea index for all patients
was 20715, for those with obstructive type apnea was 4.975.3, and for those with central type apnea
was 3.074.5. The mean Epworth Sleepiness Score was 5.974.0. No patient received continuous positive
airway pressure therapy or any other therapy for sleep-disordered breathing during the follow up period.
The mean apnea hypopnea index at 1 week after implantation of permanent pacemakers was 21714
(P¼0.8) and the mean apnea hypopnea index at end of follow-up was 1177 (Po0.0001).
Conclusion: Long term cardiac pacing signiﬁcantly reduces the number of episodes of sleep apnea in
patients with conventional permanent pacemaker indications.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Garrigue et al. reported that atrial overdrive pacing reduces the
number of sleep apnea episodes in pacemaker patients without
heart failure [1]. However, this ﬁnding has not been replicated in
subsequent investigations [2–5], although some meta-analysis
studies [6,7], reported some effect of pacing therapy on sleep
apnea. All of these studies investigated relatively short periods of
pacing. Therefore, the effect of cardiac pacing on sleep-disordered
breathing (SDB) is still controversial. We investigated the long-
term effect of cardiac pacing on SDB in patients with conventional
indications for permanent pacemakers (PPM).
2. Materials and methods
Consecutive patients with conventional indications for pace-
makers in our hospital were included. Subjects comprised 40
patients (29 men; mean age 6979 years; mean left ventricle
ejection fraction 6978%, and body mass index 23.673.5 kg/m2)
who were diagnosed with indications for PPM (sick sinus syn-
drome in 23 patients, atrioventricular block in 15 patients, brady
atrial ﬁbrillation in 2 patients).
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All patients received polysomnographic evaluations using the
Morpheus Cs (Teijin, Japan) before implantation of PPM. This
ambulatory cardiorespiratory polygraph records nasal airﬂow,
chest and abdominal wall movements, oxygen saturation, heart
rate, and Holter ECG. An apnea event was deﬁned as an absence of
airﬂow for Z10 s. Central-type sleep apnea (CSA) was deﬁned as
an apnea event with absence of chest and abdominal wall motion
for more than one-third of its duration. Obstructive-type sleep
apnea (OSA) was deﬁned as an apnea event with presence of chest
and abdominal wall motion for more than one-third of its dura-
tion. Mixed-type sleep apnea (MSA) was deﬁned as an apnea event
of other than the central or obstructive types. A hypopnea event
was deﬁned as a reduction in respiratory airﬂow of 450% for 10 s
associated with desaturation of 43%.
After implantation of PPM, all patients received polysomno-
graphic evaluations during use of the pacemaker settings
(AAI/DDD/VVI at 70 beats per minute) using the Morpheus Cs
during the in-hospital-period (acute phase) and using the SAS
2100s (Teijin, Japan) during the out-patient period (chronic phase).
The SAS 2100s records nasal airﬂow, oxygen saturation, and
pulse rate.
No patient received continuous positive airway pressure ther-
apy or any other therapy for SDB during the follow-up period. All
subjects signed informed consent as approved by our hospital
ethics committee.
Continuous variables are expressed as means7standard devia-
tion (SD) and categorical variables as counts or percentages.
Comparisons between the 2 study groups were performed using
Pearson's s2 test for categorical and Student t test for continuous
variables, respectively. Comparisons between baseline and follow-
up data were performed by paired t test. A P value o0.05 was
considered signiﬁcant. SPSS software, v.19.0.0, was used for all
statistical analyses (SPSS Inc., IL, USA).
3. Results
Baseline characteristics and co-existing diseases are shown in
Tables 1 and 2, respectively. Before implantation, the mean
Epworth sleepiness score (ESS) was 5.974.0 points. The apnea
hypopnea index (AHI) of all patients was 20715/h, OSA index was
4.975.3/h, and CSA index was 3.074.5/h. The prevalence of SDB
was 93% (using a cut-off of AHI45), 58% (using a cut-off of
AHI415) and 20% (using a cut-off of AHI430) respectively. When
SDB was deﬁned as AHI415 there were no signiﬁcant differences
in baseline characteristics except for body mass index (BMI)
(P¼0.0345, Fig. 1). Seventeen per cent of patients were only in
the OSA group (OSA only) (n¼4). Eighty-three per cent of patients
were included in the CSA group (CSA(þ)) (n¼19), while 39% of
patients were in a group that predominantly expressed CSA
characteristics (CSA4OSA) (n¼9) (Table 3). When SDB was
deﬁned with an AHI cut-off level 415, there were no signiﬁcant
differences in baseline characteristics or co-existing diseases
(Tables 1 and 2).
A representative case is illustrated in Fig. 1. The patient was a 73
year-old manwith sick sinus syndrome. Before implantation of PPM,
his BMI was 24.9 kg/m2, his cardio-thoracic ratio (CTR) was 53%, his
brain natriuretic peptide level (BNP) was 271.2 pg/mL, and his ESS
was 4 points. His AHI was 38.4/h, his apnea index (AI) was 20.7/h, his
OSA index was 15.7/h, his CSA index was 2.7/h, and his hypopnea
index (HI) was 4.8/h (Fig. 1A). At the end of follow-up (962 days (32
months) after implantation of PPM), his AHI was 7.6/h, his AI was
6.4/h, and his HI was 1.2/h (Fig. 1B). He was not given continuous
positive airway pressure therapy or any other treatment for
sleep apnea.
The mean follow-up period of the 40 patients was 35713
months. The mean AHI at 1 week after implantation of PMM was
21714/h (P¼0.8850) and the mean AHI at the end of the follow-
up period was 1177/h (Po0.0001) (Table 3). The AHI and
incidence of desaturation 43% were improved in all patient
groups (all patients, AHI415, OSA only, CSA (þ), and CSA4OSA)
at the end of follow-up (Table 3). Mean BMI at end of follow-up
was 23.373.5 kg/m2 in all patients (P¼0.2427, vs. baseline),
22.272.9 kg/m2 in the SDB() group (P¼0.9359, vs. baseline)
and 24.073.8 kg/m2 in the SDB(þ) group (P¼0.1041, vs. baseline),
respectively. We did not vary the pacing rate from 70 bpm. The
average heart rate of end of follow-up was derived from detected
pulses using the SAS 2100. These data are potentially affected by
occurrence of premature beats (Table 3). AHI changes in individual
patients are shown in Fig. 2.
4. Discussion
Young et al. reported that prevalence of SDB (deﬁned using a
cut-off of AHI≧5) was 9% in women and 24% in men in the general
population [8]. In this study, prevalence of SDB was very high in
patients with conventional indications for PPM. The prevalence of
SDB was 58% when the cut-off level was deﬁned as AHI415 and
20% when the cut-off level was deﬁned as AHI430, respectively.
In a previous study, the majority of patients with implanted PPM
suffered from unrecognized SBD [9]. In that study, the prevalence
of SDB was 59% when the cut-off level was deﬁned as AHI410 and
27% when the cut-off level was deﬁned as AHI430, respectively.
In our study, the mean AHI was lowered signiﬁcantly at the end
of the follow-up period and these ﬁndings were seen in all patient
categories, occurring without changes in BMI. We used different
polysomnographic systems for evaluation in the acute and chronic
phases. There could be some differences in sensitivity for AHI
between these systems. However, there was good correlation
between AHI and the index of desaturation 43% determined by
the polysomnographic systems. The index of desaturation o3%
was also improved in all patient groups (all patients, AHI415, OSA
only, CSA (þ), and CSA4OSA) at the end of follow-up.
Table 1
Patients' baseline characteristics.
All SDB() SDB(þ) () vs. (þ)
(n¼40) (n¼17) (n¼23) P
Age (y) 69.079.3 68.0710.8 69.778.3 0.5528
BMI (kg/m2) 23.673.5 22.272.9 24.673.7 0.0345
CTR (%) 52.776.0 52.276.8 53.075.6 0.6796
LVEF (%) 69.378.2 67.878.7 70.377.8 0.3554
BNP (pg/mL) 2257366 2157356 2327382 0.9078
SDB¼Sleep disordered breathing; SDB(þ)¼Apnea-Hypopnea Index 415; BMI¼-
body mass index; CTR¼cardio-thoracic ratio; LVEF¼ left ventricular ejection frac-
tion; BNP¼brain natriuretic peptide; and ESS¼Epworth Sleepiness Score.
Table 2
Patients' co-existing diseases.
All (%) SDB() (%) SDB(þ) (%) () vs. (þ)
(n¼40) (n¼17) (n¼23) P
Hypertension 55 41.20 65.20 0.2343
Diabetes mellitus 27.50 29.40 26.10 40.9999
Dyslipidemia 22.50 5.90 34.80 0.0749
Gout or high uremic acid 20 11.80 26.10 0.4717
Ischemic heart disease 2.50 5.90 0 0.8779
SDB¼Sleep disordered breathing and SDB(þ)¼Apnea-Hypopnea Index 415.
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Fig. 1. (a) Representative case: before implantation of permanent pacemaker. The patient was 73 year-old man with sick sinus syndrome. BMI 24.9 kg/m2, CTR 53%, BNP
271.2 pg/mL, and ESS 4 points. Before implantation of a permanent pacemaker, AHI was 38.4/h, AI was 20.7/h, OSA was 15.7/h, CSA was 2.7/h, and HI was 4.8/h.
(b) Representative case: after implantation of permanent pacemaker. Thirty-two months after implantation of a permanent pacemaker, AHI was 7.6/h, AI was 6.4/h, and HI
was 1.2/h.
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Our investigation suggested long-term cardiac pacing signiﬁ-
cantly reduced the number of episodes of sleep apnea in patients
with conventional PPM indications. In a previous study, a single night
of overdrive pacing lowered AHI in recipients of conventional dual
chamber pacemakers [1]; however, these ﬁndings were not repli-
cated [2–5]. Several months of overdrive atrial pacing had no effect
on obstructive or mixed sleep apnea [6,8]. Nearly all previous studies
employed pacing periods of between 1 night and 3 months. In our
data, the mean AHI at 1 week after implantation of PPM was not
changed from baseline. This ﬁnding, which suggests that short term
pacing is not effective for SDB, is compatible with most previous
studies [2–5].
Our investigation suggests that cardiac pacing improves not
only CSA but also OSA. The mechanism by which SDB is improved
is unclear. CSA might be improved by reduction of periodic
variations in heart rate, which are increased by apnea and may
result in part from changes in autonomic tone. OSA might be
improved by a reduction of subclinical edema of the upper airway
tract dependent on bradycardia. Recently, Yumino et al. described
the concept of “Fluid Shift” [10]. Their ﬁndings suggested noctur-
nal rostral ﬂuid shift as a unifying concept contributing to the
pathogenesis of both OSA and CSA in patients with heart failure.
Our patients' mean heart rate during the sleep period was
signiﬁcantly increased from baseline (by 30%). Therefore, their
cardiac output was increased during the sleep period. Increasing
cardiac output decreases “Fluid Shift.” Thus, long-term cardiac
pacing improved not only CSA but also OSA. These effects were not
observed in the short-term (1 week) pacing period in our study.
Yunino et al. also reported that the variations in the degree of ﬂuid
retention and overnight rostral ﬂuid shift were related to changes
in the predominant type of sleep apnea. One week of cardiac
pacing might be a period too short to radically improve the degree
of ﬂuid retention and overnight rostral ﬂuid shift.
5. Study limitations
Our study had no control group and lacked a cross-over design.
Our study population comprised patients with conventional indi-
cations for a pacemaker and the purpose of this study was to
examine long-term effects of cardiac pacing on SDB. Additionally,
the use of lower heart rate settings or pacing off-setting in patients
with conventional indications for PMM could not tested for ethical
reasons.
6. Conclusions
Long term cardiac pacing signiﬁcantly reduced the number of
episodes of sleep apnea in patients with conventional PMM
indications.
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